Navigation Links
OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
Date:4/23/2012

SAN DIEGO, April 23, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe. The study demonstrated the therapy's ability to provide local tumor control and quality of life outcomes that compare favorably to standard outcomes associated with surgery. These results were presented at the 5th European Conference on Head and Neck Oncology in Poznan, Poland on Friday, April 20, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The primary goal of this phase IV head and neck cancer study was to assess the ability of the OMS ElectroChemotherapy to control growth or recurrence of the cancer eight months following treatment, equivalent to surgery as compared to historical controls, with respect to primary (new) tumors and locally recurrent tumors. In this interim analysis, local tumor control was achieved in 46/49 (94%) primary tumors and 12/21 (57%) recurrent tumors. This meant that there was no recurrence of the tumors during the monitoring period. These were excellent results that were on par with the expected outcomes of surgery. Furthermore, evaluation of safety using the OMS ElectroChemotherapy for this patient population demonstrated that the treatment was safe and well-tolerated with no grade three or higher adverse events related to treatment reported during this study.

In addition, the secondary endpoint of preservation of organ function and appearance using validated quality of life instruments demonstrated a positive
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OncoSec Selected to Present Data at Upcoming Head and Neck Cancer Conferences
2. OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial
3. OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy
4. OncoSecs OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper
5. OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma
6. OncoSec to Present at World Cancer Immunotherapy Conference
7. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
8. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
9. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
10. OncoSec to Present at Medical Device Investor Forum
11. Device Master File for OncoSec Medical System Completed and Submitted to FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Takeda Pharmaceutical Company Limited ... fulfill the post-marketing commitment and submissions of data ... Multi-Database Bladder Cancer Risk Characterization Study , a ... conducted in four European countries, for pioglitazone containing ... 10 years of follow-up. Findings demonstrate that there ...
(Date:7/30/2015)... SAN FRANCISCO , July 30, 2015 ... devices market is expected to reach USD 23.01 ... Grand View Research, Inc. Growing base of geriatric population, ... and infections, and rising level of awareness among target ... impact rendering drivers over the forecast period. According to ...
(Date:7/30/2015)... What can be expected from ... going to grow at the fastest rates? Visiongain ... 2025, assessing data, trends, opportunities and prospects there. ... charts, and graphs. Discover the most lucrative areas in ... study lets you assess forecasted sales at overall world ...
Breaking Medicine Technology:Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
(Date:7/30/2015)... Miami, FL (PRWEB) , ... July 30, 2015 , ... ... Florida, according to the Health News Florida on June 17th. Those untreated ... needle exchange programs to prevent the spread of dirty needles throughout the community. Ultimately ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, ... gum contouring and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh ... him popular with many patients from around the world. , “Like treatment of any ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute (TCI) ... National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of 69 ...
(Date:7/30/2015)... ... 30, 2015 , ... Bird B Gone, the leader in bird control products ... to repel pest birds from the AC units and ventilation systems on hospital roofs. ... even the West Nile virus. When these droppings dry, the fine powder can be ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... managers at multinational organizations and NGO’s, according to a new survey by leading ... shows that property damage and employee medical expenses represented the largest sources of ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3
... localised prostate cancer, one of the more common cancers ... researchers at Sweden's Karolinska Institutet said. ... blood of a group of cancer patients and monitored ... was part of the Scandinavian Prostate Cancer Group collaboration. ...
... recent report has zeroed in on a potential threat to ... the influence of anti-allergy drugs. ,A survey ... that one in seven suffered from hayfever or other allergies ... ,Many of those questioned said they had ...
... smoking ban which began March 2004, has worked on many ... pollution, the health of bar workers has improved considerably. ... percent reduction in air pollution and an 80 percent cut ... published in the American Journal of Respiratory and Critical Care ...
... a Body Mass Index (BMI) of more than 30 than ... more likely, according to research published in the April issue ... figures for more than a thousand children over two decades ... but that levels were much more constant among teenagers included ...
... Safety study triggered decision to go beyond standard ... critical care experts at The Johns Hopkins Hospital ... hospital superbugs for every child admitted to its ... more stringent admission screening methods for methicillin-resistant Staphylococcus ...
... pentoxifylline appears to have limited benefit in the first-line ... according to a report in the April issue of ... a second report in the same issue finds that ... effective in patients with another ulcer-causing mouth disease, oral ...
Cached Medicine News:Health News:Method to Screen Prostate Cancer Less Effective 2Health News:Ireland’s Smoke Ban Seems To Do The Tric 2Health News:20-year Study Shows Significant Rise in Childhood Obesity, Especially Among Girls 2Health News:Johns Hopkins Begins Aggressive Screening for 'superbugs' in Children 2Health News:Johns Hopkins Begins Aggressive Screening for 'superbugs' in Children 3Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 2Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 3
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Medicine Products: